Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent

Investigational New Drugs

Volumn 22, Issue 3, 2004, Pages 231-240

  Wilkinson, Gary P ^a   Taylor, James P ^a   Shnyder, Steve ^a   Cooper, Patricia ^a   Howard, Phil W ^a   Thurston, David E ^b   Jenkins, Terence C ^a   Loadman, Paul M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

DNA cross linking; HPLC; Mass spectrometry; PBD; Plasma; Protein binding

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIMER; DNA; IMINE; ION; SIG 136; SJG 136; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CELL LINE; DNA CROSS LINKING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BENZODIAZEPINONES; BLOOD PROTEINS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CROSS-LINKING REAGENTS; DIMERIZATION; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FEMALE; MASS SPECTROMETRY; MICE; MICE, NUDE; PROTEIN BINDING; PYRROLES;

EID: 3543044968     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000026249.97007.60     Document Type: Article

References (19)

1. Hurley LH: DNA and associated targets for drug design. J Med Chem 32: 2027-2033, 1989
2. Thurston DE: Nucleic acid targeting: Therapeutic strategies for the 21st century. Br J Cancer 80 (Suppl 1): 65-85, 1999
3. Remers WA: The Chemistry of Antitumour Antibiotics, vol 2. Wiley, New York, 1988, pp. 28-92
4. Thurston DE: Advances in the Study of Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumour Antibiotics. In: Neidle S, Waring MJ (eds) Molecular Aspects of Anticancer Drug-DNA Interactions, vol. 1. Macmillan Press, UK, 1993, pp. 54-88
5. Hurley LH, Reck T, Thurston DE, Langley DR, Holden KG, Hertzberg RP, Hoover JR, Gallagher G, Faucette LF, Mong SM, Johnson PK: Pyrrolo[1,4] benzodiazepine antitumor antibiotics: Relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem Res Toxicol 1: 258-266, 1988
6. Puvvada MS, Forrow SA, Hartley JA, Stephenson P, Gibson I, Jenkins TC, Thurston DE: Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines. Biochemistry 36: 2478-2484, 1997
7. Bose DS, Thompson AS, Ching JS, Hartley JA, Berardini MD, Jenkins TC, Neidle S, Hurley LH, Thurston DE: Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Amer Chem Soc 114: 4939-4941, 1992
8. Bose DS, Thompson AS, Smellie M, Berardini MD, Hartley JA, Jenkins TC, Neidle S, Thurston DE: Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers. Chem Commun 1518-1520, 1992
9. Jenkins TC, Hurley LH, Neidle S, Thurston DE: Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: Evidence for sequence-specific interstrand cross-linking. J Med Chem 37: 4529-1537, 1994
10. Thurston DE, Bose DS, Thompson AS, Howard PW, Leoni A, Croker SJ, Jenkins TC, Needle SS, Hartley JA, Hurley LH: Synthesis of sequence-selective C8-linked pyrrolo[2,1-c][1,4]benzodiazepine DNA interstrand cross-linking agents. J Org Chem 61: 8141-8147, 1996
11. Smellie M, Bose DS, Thompson AS, Jenkins TC, Hartley JA, Thurston DE: Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking with pyrrolobenzodiazepine (PBD) dimers: Kinetic and molecular modelling studies. Biochemistry 42: 8232-8239, 2003.
12. Neidle S, Puvvada MS, Thurston DE: The relevance of drug DNA sequence specificity to anti-tumour activity. Eur J Cancer 30A: 567-568, 1994
13. Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE: Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 44: 737-748, 2001
14. Gregson SJ, Howard PW, Jenkins TC, Kelland LR, Thurston DE: Synthesis of a novel C2/C2′-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity. J Chem Soc Chem Commun 797-798, 1999
15. Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley B, Kelland LR, Guichard S, Jodrell DI, Alley MC, Schultz R, Hollingshead MG, Sausville EA, Gregson SJ, Howard PW, Thurston DE: SJG-136 (NSC 694501) A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2003 (in press)
16. Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, Gregson SJ, Thurston DE, Sausville EA: SJG-136 (NSC 694501) A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity. Part 2: Efficacy evaluations. Cancer Res 2003 (in press)
17. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double JA, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J: United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edition). Brit J Cancer 77: 1-10, 1998
18. Rowland M, Tozer TN: Clinical Pharmacokinetics - Concepts and Applications. Lea & Febiger, Philadelphia, 1989
19. Wallon MI, Goddard P, Kelland LR, Thurston DE, Harrap KR: Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. Cancer Chemother Pharmacol 38: 431-438, 1996